Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$0.92
-8.1%
$3.43
$0.90
▼
$16.60
$20.12M4.38362,890 shs200,814 shs
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.97
+1.0%
$4.68
$2.92
▼
$6.45
$318.79M0.76380,454 shs310,762 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$8.67
-4.1%
$10.78
$6.72
▼
$17.78
$340.24M1.07450,586 shs243,000 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$7.60
-4.7%
$11.59
$7.56
▼
$17.15
$221.43M0.75221,952 shs322,592 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
+9.89%-34.21%-74.36%-85.34%-90.44%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-1.50%-6.65%-12.08%-27.62%+24.76%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-2.16%-7.57%+6.86%-47.41%-27.27%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.04%-28.75%-31.62%-40.76%-34.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
$0.92
-8.1%
$3.43
$0.90
▼
$16.60
$20.12M4.38362,890 shs200,814 shs
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.97
+1.0%
$4.68
$2.92
▼
$6.45
$318.79M0.76380,454 shs310,762 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$8.67
-4.1%
$10.78
$6.72
▼
$17.78
$340.24M1.07450,586 shs243,000 shs
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$7.60
-4.7%
$11.59
$7.56
▼
$17.15
$221.43M0.75221,952 shs322,592 shs
The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
+9.89%-34.21%-74.36%-85.34%-90.44%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-1.50%-6.65%-12.08%-27.62%+24.76%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-2.16%-7.57%+6.86%-47.41%-27.27%
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-3.04%-28.75%-31.62%-40.76%-34.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
2.00
Hold$11.061,103.75% Upside
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.33
Hold$8.00101.51% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.20
Hold$21.40146.97% Upside
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
2.50
Moderate Buy$19.00149.87% Upside

Current Analyst Ratings Breakdown

Latest AARD, ENTA, AVIR, and CTNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/20/2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
Lower Price TargetOverweight$19.00 ➝ $17.00
11/16/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
DowngradeSell (D-) ➝ Sell (E+)
11/16/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Set Price Target$2.00
11/16/2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Boost Price TargetEqual Weight$7.00 ➝ $8.00
11/13/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Reiterated RatingMarket Perform
11/4/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
DowngradeStrong-Buy ➝ Market Perform
11/4/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Set Price Target$23.00
10/26/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
DowngradeOutperform ➝ Market Perform
10/26/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Lower Price TargetHold$4.00 ➝ $2.00
10/26/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Lower Price TargetNeutral$4.00 ➝ $2.00
10/23/2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
Set Price Target$2.50
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/A$2.63 per shareN/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$2.19 per shareN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/A$6.25 per shareN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
$63M3.51N/AN/A$2.75 per share2.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$57.59M-$3.34N/AN/AN/AN/A-89.27%-80.39%N/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$158.35M-$1.95N/AN/AN/AN/A-69.91%-61.22%N/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$59.98M-$1.77N/AN/AN/AN/A-25.48%-24.28%N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$81.89M-$2.35N/AN/AN/A-108.33%-64.32%-22.44%2/8/2027 (Estimated)

Latest AARD, ENTA, AVIR, and CTNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/16/2026Q4 2026
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
-$0.7240-$0.81-$0.0860-$0.8140$14.62 million$12.87 million
11/13/2026Q3 2026
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
-$0.69-$0.88-$0.19-$0.88N/AN/A
11/9/2026Q3 2026
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.51-$0.40+$0.11-$0.40$50.45 millionN/A
11/3/2026Q3 2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.4538-$0.49-$0.0363-$0.49$5.65 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/AN/AN/AN/AN/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
9.11
12.63
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
8.00
8.00
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
31.11
31.11
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
N/A
3.78
3.76

Institutional Ownership

CompanyInstitutional Ownership
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
N/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
94.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aardvark Therapeutics, Inc. stock logo
AARD
Aardvark Therapeutics
2821.89 million17.99 millionOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
5580.30 million62.96 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
5139.27 million36.16 millionOptionable
Enanta Pharmaceuticals, Inc. stock logo
ENTA
Enanta Pharmaceuticals
12029.12 million25.78 millionOptionable

Recent News About These Companies

What is HC Wainwright's Forecast for ENTA Q1 Earnings?
Enanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue Falls
Enanta Pharmaceuticals, Inc. Announces Executive Changes
Enanta Pharmaceuticals stock trades at USD 12.11

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aardvark Therapeutics stock logo

Aardvark Therapeutics NASDAQ:AARD

$0.94 -0.06 (-6.30%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.97 +0.04 (+1.02%)
Closing price 03:58 PM Eastern
Extended Trading
$3.98 +0.00 (+0.13%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$8.66 -0.38 (-4.15%)
Closing price 03:58 PM Eastern
Extended Trading
$8.68 +0.02 (+0.17%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Enanta Pharmaceuticals stock logo

Enanta Pharmaceuticals NASDAQ:ENTA

$7.60 -0.38 (-4.71%)
Closing price 03:59 PM Eastern
Extended Trading
$7.62 +0.02 (+0.21%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.